Human immunology · 2026
Graft CD3+/CD4 - CD8- T-cell ratio: a predictor of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in pediatric patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xiaoling, Zhao Liang, Han Chao, Yang Guimin, Cai Lixiao, Zhao Qing
Аннотация
BACKGROUND: Acute graft-versus-host disease (aGVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study investigated the association between the graft CD3+/CD4 - CD8- T-cell ratio and the incidence of aGVHD in pediatric recipients.
METHODS: A total of 112 pediatric patients with high-risk hematologic malignancies undergoing allo-HSCT were enrolled in this retrospective study. Associations between the graft CD3+/CD4 - CD8- T-cell ratio and aGVHD were evaluated using Fine-Gray regression models. Receiver operating characteristic (ROC) analysis was performed to determine the predictive performance and optimal cutoff value of the graft CD3+/CD4 - CD8- T-cell ratio. Spearman's rank correlation coefficient was used to assess correlations among different cellular subsets.
RESULTS: The day-100 cumulative incidence of grade II-IV aGVHD was 41.1%. In multivariable analysis, the graft CD3+/CD4 - CD8- T-cell ratio was independently associated with grade II-IV aGVHD. ROC analysis identified 56 as the optimal cutoff value for the graft CD3+/CD4 - CD8- T-cell ratio. Patients with a high ratio had a significantly higher incidence of grade II-IV aGVHD than those with a low ratio (56.3% vs. 20.8%, P < 0.001), whereas no significant differences were observed in disease relapse or cytomegalovirus (CMV) infection. The graft CD4 - CD8- T-cell dose was positively correlated with early peripheral CD4 - CD8- T-cell recovery after transplantation.
CONCLUSIONS: A higher graft CD3+/CD4 - CD8- T-cell ratio is independently associated with an increased risk of day-100 grade II-IV aGVHD in pediatric allo-HSCT recipients. Optimizing the graft CD3+/CD4 - CD8- T-cell ratio may help mitigate aGVHD, thereby serving as a practical biomarker for individualized aGVHD risk stratification.
METHODS: A total of 112 pediatric patients with high-risk hematologic malignancies undergoing allo-HSCT were enrolled in this retrospective study. Associations between the graft CD3+/CD4 - CD8- T-cell ratio and aGVHD were evaluated using Fine-Gray regression models. Receiver operating characteristic (ROC) analysis was performed to determine the predictive performance and optimal cutoff value of the graft CD3+/CD4 - CD8- T-cell ratio. Spearman's rank correlation coefficient was used to assess correlations among different cellular subsets.
RESULTS: The day-100 cumulative incidence of grade II-IV aGVHD was 41.1%. In multivariable analysis, the graft CD3+/CD4 - CD8- T-cell ratio was independently associated with grade II-IV aGVHD. ROC analysis identified 56 as the optimal cutoff value for the graft CD3+/CD4 - CD8- T-cell ratio. Patients with a high ratio had a significantly higher incidence of grade II-IV aGVHD than those with a low ratio (56.3% vs. 20.8%, P < 0.001), whereas no significant differences were observed in disease relapse or cytomegalovirus (CMV) infection. The graft CD4 - CD8- T-cell dose was positively correlated with early peripheral CD4 - CD8- T-cell recovery after transplantation.
CONCLUSIONS: A higher graft CD3+/CD4 - CD8- T-cell ratio is independently associated with an increased risk of day-100 grade II-IV aGVHD in pediatric allo-HSCT recipients. Optimizing the graft CD3+/CD4 - CD8- T-cell ratio may help mitigate aGVHD, thereby serving as a practical biomarker for individualized aGVHD risk stratification.